Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 67
Filtrar
1.
Eur J Med Chem ; 271: 116403, 2024 May 05.
Artigo em Inglês | MEDLINE | ID: mdl-38615411

RESUMO

The biologically active metabolite of vitamin D3 - calcitriol - is a hormone involved in the regulation of calcium-phosphate homeostasis, immunological processes and cell differentiation, being therefore essential for the proper functioning of the human body. This suggests many applications of this steroid in the treatment of diseases such as rickets, psoriasis and some cancers. Unfortunately, using therapeutic doses of calcitriol is associated with high concentrations of this compound which causes hypercalcemia. For this reason, new calcitriol analogs are constantly sought, devoid of calcemic effects but maintaining its beneficial properties. In this study, we present the synthesis of vitamin D derivatives characterized by an enlarged (seven-membered) ring D. Preparation of the designed vitamin D compounds required separate syntheses of crucial building blocks (C/D-rings fragments with side chain and rings A) which were combined by different methods, including Wittig-Horner reaction and Suzuki coupling. Biological activities of the target vitamin D analogs were assessed both in vitro and in vivo, demonstrating their significant potency compared to the natural hormone. Furthermore, the successful crystallization of these compounds with the vitamin D receptor (VDR) enabled us to investigate additional molecular interactions with this protein.


Assuntos
Desenho de Fármacos , Receptores de Calcitriol , Receptores de Calcitriol/metabolismo , Receptores de Calcitriol/agonistas , Humanos , Relação Estrutura-Atividade , Animais , Estrutura Molecular , Cristalografia por Raios X , Calcitriol/farmacologia , Calcitriol/química , Calcitriol/síntese química , Calcitriol/análogos & derivados , Camundongos , Relação Dose-Resposta a Droga , Modelos Moleculares
2.
J Steroid Biochem Mol Biol ; 228: 106247, 2023 04.
Artigo em Inglês | MEDLINE | ID: mdl-36639037

RESUMO

The 24th Workshop on Vitamin D was held September 7-9, 2022 in Austin, Texas and covered a wide diversity of research in the vitamin D field from across the globe. Here, we summarize the meeting, individual sessions, awards and presentations given.


Assuntos
Deficiência de Vitamina D , Vitamina D , Humanos , Vitaminas
3.
Front Immunol ; 13: 960405, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36341456

RESUMO

The vitamin D receptor as well as its ligand have been localized to various immune tissues and cells. These observations have led researchers to hypothesize a role for vitamin D in the immune system. However, a specific role for vitamin D in immunity has yet to be clearly delineated. The work in this report was undertaken to determine if mounting an antibody response is altered in the face of vitamin D-deficiency or when the signaling pathway is eliminated by removal of the nuclear receptor. This investigation provides direct evidence vitamin D is not necessary for producing antibodies, a process paramount for optimal attack against many foreign organisms. The idea that vitamin D plays a significant role in immunity has been proposed repeatedly for many years. To address this important idea we have carried out studies in mice to determine if vitamin D plays a significant role in antibody production. Two animal models were utilized: mice depleted of vitamin D and mice devoid of the vitamin D receptor. Further, a possible role of hypocalcemia resulting from vitamin D deficiency in antibody production was determined. Neither the absence of vitamin D or the vitamin D receptor nor hypocalcemia affected the ability of mice to mount an antibody response to an antigen challenge. Thus, we found no evidence that vitamin D or normal serum calcium is required for this major form of immunity.


Assuntos
Hipocalcemia , Deficiência de Vitamina D , Camundongos , Animais , Vitamina D , Receptores de Calcitriol/metabolismo , Formação de Anticorpos , Vitaminas
4.
Biol Open ; 11(7)2022 07 15.
Artigo em Inglês | MEDLINE | ID: mdl-35662320

RESUMO

Epidemiological observations have prompted some to posit that elevated circulating vitamin D is responsible for reduced colon cancer in individuals residing near the equator. We have previously demonstrated that vitamin D has no effect on colon cancer in two rodent models of intestinal tumorigenesis. We have now extended this line of inquiry to ask whether ablation of vitamin D receptor (VDR) affects tumorigenesis. A VDR null rat was developed using Cas9-CRISPR technology, which allowed us to investigate whether 1,25(OH)D3 signaling through its receptor plays a role in intestinal tumorigenesis. Loss of VDR expression alone did not induce tumorigenesis, even in animals exposed to the inflammatory agent dextran sodium sulfate. These VDR-/- rats were then crossed with ApcPirc/+ rats, which are predisposed to the development of intestinal neoplasms. In combination with the Pirc/+ mutation, VDR loss did not enhance tumor multiplicity, growth, or progression in the colon or small intestine. This study demonstrates that the vitamin D receptor does not impact tumor development, and strongly supports previous findings that vitamin D itself does not play a role in colon cancer development or progression. Alternative explanations are needed for the original latitude hypothesis, as well as observational data in humans. This article has an associated First Person interview with the first author of the paper.


Assuntos
Neoplasias do Colo , Receptores de Calcitriol , Animais , Animais Geneticamente Modificados , Carcinogênese/genética , Transformação Celular Neoplásica , Neoplasias do Colo/genética , Neoplasias do Colo/metabolismo , Humanos , Ratos , Receptores de Calcitriol/genética , Receptores de Calcitriol/metabolismo , Vitamina D/metabolismo
5.
Photochem Photobiol Sci ; 21(8): 1399-1404, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35488978

RESUMO

The primary source of vitamin D3 for humans is that produced in skin by ultraviolet irradiation. Ultraviolet (UV) B (UVB, 280-310 nm) light causes the isomerization of 7-dehydrocholesterol (7-DHC) to pre-vitamin D3 that is thermally isomerized to vitamin D3. In addition to free vitamin D3, it has been previously reported that esterified vitamin D3 is also found in the skin of rats irradiated with UVB. We found that a large fraction of the vitamin D3 precursor, 7-dehydrocholesterol is in the esterified form. Following UVB irradiation, vitamin D3 esters represent the majority of tissue vitamin D3, comprising approximately 80% in mice. Examination of vitamin D3 ester transport from skin in DBP-/- mice demonstrated that skin vitamin D3 ester content decreased only in the presence of DBP. No significant binding of vitamin D3 esters by serum was observed and no vitamin D3 esters were detectable in mouse serum after UVB treatment, indicating that the esters are hydrolyzed prior to transport into the circulation. The significance of vitamin D3 esters and their hydrolysis is the subject of current investigation.


Assuntos
Ésteres , Vitamina D , Animais , Colecalciferol , Humanos , Camundongos , Ratos , Pele/efeitos da radiação , Raios Ultravioleta , Vitamina D/metabolismo
6.
Bioorg Chem ; 118: 105416, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34798456

RESUMO

A new series of highly biologically active (20S,22R)-1α,25-dihydroxy-22-methyl-2-methylene-vitamin D3 analogs, possessing different side chains, have been efficiently prepared as potential agents for medical therapy. Design of these synthetic targets was based on the analysis of the literature data and molecular docking experiments. The synthetic strategy involved Sonogashira coupling of the known A-ring dienyne with the C,D-ring enol triflates, obtained from the corresponding Grundmann ketones. All synthesized vitamin D compounds were characterized by high in vitro potency and, moreover, they proved to be very calcemic in vivo exerting high activity on bone with particularly elevated intestinal calcium transport.


Assuntos
Calcitriol/farmacologia , Desenho de Fármacos , Simulação de Acoplamento Molecular , Receptores de Calcitriol/agonistas , Animais , Calcitriol/síntese química , Calcitriol/química , Diferenciação Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Relação Dose-Resposta a Droga , Células HL-60 , Humanos , Estrutura Molecular , Ratos , Proteínas Recombinantes/metabolismo , Relação Estrutura-Atividade
7.
Physiol Rep ; 9(23): e15138, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34873873

RESUMO

Vitamin D3 is a prohormone that is essential for calcium homeostasis. It is naturally produced in the skin by ultraviolet-B (UVB) irradiation of 7-dehydrocholesterol. In the absence of skin production, vitamin D3 can also be obtained from oral sources. However, the actual biological equivalence of naturally produced (i.e., UVB-irradiation of skin) and oral vitamin D3  has not been determined. We previously identified a unique and specific transport mechanism for skin-generated vitamin D3 which requires vitamin D binding protein (DBP); a mechanism that differs from absorption and transport of oral vitamin D3 . In the following report, we examined the impact of this difference on the biological activity of vitamin D3 . We report that UVB-generated vitamin D3 is more potent at raising serum calcium compared to oral vitamin D3 , with the total biological activity being twofold higher. By examining the excretion of radiolabeled vitamin D3 injected unbound or pre-bound by DBP, we attributed the increased activity of skin-generated vitamin D3 to a significant reduction in biliary excretion of DBP-bound vitamin D relative to unbound vitamin D. Thus, removal of vitamin D3 from the skin by the natural DBP system markedly improves biological activity compared to that given orally.


Assuntos
Colecalciferol/farmacologia , Pele/metabolismo , Raios Ultravioleta , Proteína de Ligação a Vitamina D/genética , Animais , Cálcio/sangue , Camundongos , Camundongos Knockout , Pele/efeitos da radiação , Proteína de Ligação a Vitamina D/metabolismo
8.
J Med Chem ; 63(13): 7355-7368, 2020 07 09.
Artigo em Inglês | MEDLINE | ID: mdl-32510210

RESUMO

Continuing our search for vitamin D analogues, we explored the modification of the steroidal side chain and inserted a methylene moiety in position C-22 together with either lengthening the side chain or introducing a ring at the terminal end. Our conformational studies confirmed that the presence of a methylene group attached to C-22 restricts the conformational flexibility of the side chain, which can result in changes in biological characteristics of a molecule. All synthesized 1α,25-dihydroxy-2,22-dimethylene-19-norvitamin D3 analogues proved equal to calcitriol in their ability to bind to the vitamin D receptor, and most of them exert significantly higher differentiation and transcriptional activity than calcitriol. The most active compounds were characterized by the presence of an elongated side chain or 26,27-dimethylene bridge. The synthetic strategy was based on the Wittig-Horner coupling of the known A-ring phosphine oxide with the corresponding Grundmann ketones prepared from a 20-epi-Inhoffen-Lythgoe diol derived from vitamin D2.


Assuntos
Calcitriol/análogos & derivados , Cálcio/metabolismo , Animais , Ligação Competitiva , Osso e Ossos/efeitos dos fármacos , Osso e Ossos/metabolismo , Calcitriol/farmacologia , Técnicas de Química Sintética , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos/métodos , Regulação da Expressão Gênica/efeitos dos fármacos , Células HL-60 , Humanos , Intestinos/efeitos dos fármacos , Luciferases/genética , Masculino , Conformação Molecular , Ratos Sprague-Dawley , Receptores de Calcitriol/genética , Receptores de Calcitriol/metabolismo , Relação Estrutura-Atividade , Transcrição Gênica
9.
J Bone Miner Res ; 35(4): 623-630, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-31369169

RESUMO

A new 1α,25-dihydroxy vitamin D3 analog (2-methylene-22(E)-(24R)-22-dehydro-1α,24,25-trihydroxy-19-norvitamin D3 or WT-51) has been tested as a possible therapeutic for osteoporosis. It is 1/10th as active as 1,25(OH)2 D3 in binding affinity for the vitamin D receptor but is at least 200 times more active than 1,25(OH)2 D3 and equal to that of 2MD (2-methylene-19-nor-(20S)-1α,25(OH)2 D3 , an analog previously tested in postmenopausal women), in supporting bone formation by isolated osteoblasts in culture. However, in contrast to 2MD, it is virtually inactive on bone resorption in vivo. WT-51 markedly increased bone mass (lumbar and femur) in ovariectomized (OVX) female rats. Further, bone strength tested by the three-point bending system is significantly increased by WT-51. Thus, WT-51 is an attractive candidate for the treatment of postmenopausal osteoporosis. © 2019 American Society for Bone and Mineral Research.


Assuntos
Densidade Óssea , Reabsorção Óssea , Animais , Calcitriol , Feminino , Humanos , Ovariectomia , Ratos , Vitamina D/farmacologia
10.
Proc Natl Acad Sci U S A ; 116(49): 24527-24532, 2019 12 03.
Artigo em Inglês | MEDLINE | ID: mdl-31748273

RESUMO

Vitamin D is produced in the skin following exposure to sunlight. Ultraviolet (UV) B (UVB, 280-310 nm) results in isomerization of 7-dehydrocholesterol to previtamin D that spontaneously isomerizes to vitamin D. This pool of skin-derived vitamin D is the major source of vitamin D for animals. However, the mechanisms by which it becomes available remain undefined. It has been assumed that cutaneous vitamin D is transported into the circulation by vitamin D binding protein (DBP), but experimental evidence is lacking. To determine whether cutaneous vitamin D is transported by DBP, we utilized DBP-/- mice that were made vitamin D-deficient. These animals lack measurable 25(OH)D in blood and are hypocalcemic. As controls, DBP+/+ animals were vitamin D depleted and made equally hypocalcemic. UV irradiation of DBP+/+ animals restored serum calcium and serum 25(OH)D while the same treatment of DBP-/- animals failed to show either a serum calcium or 25(OH)D response despite having normal vitamin D production in skin. Intravenous injection of small amounts of recombinant DBP to the vitamin D-deficient DBP-/- mice restored the response to UV light. These results demonstrate a requirement for DBP to utilize cutaneously produced vitamin D.


Assuntos
Pele/metabolismo , Proteína de Ligação a Vitamina D/metabolismo , Vitamina D/metabolismo , Animais , Hipocalcemia/genética , Hipocalcemia/metabolismo , Injeções Intravenosas , Camundongos Knockout , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/genética , Pele/efeitos da radiação , Raios Ultravioleta , Deficiência de Vitamina D/genética , Deficiência de Vitamina D/metabolismo , Proteína de Ligação a Vitamina D/administração & dosagem , Proteína de Ligação a Vitamina D/genética
11.
Proc Natl Acad Sci U S A ; 116(45): 22552-22555, 2019 11 05.
Artigo em Inglês | MEDLINE | ID: mdl-31636184

RESUMO

Vitamin D and sunlight have each been reported to protect against the development of experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). To date, the contribution of each has been unclear as ultra violet (UV) exposure also causes the generation of vitamin D in the skin. To examine whether the UV based suppression of EAE results, at least, in part from the production of vitamin D, we studied the effect of UV light on EAE in mice unable to produce 7-dehydroxycholesterol (7-DHC), the required precursor of vitamin D. Furthermore, we examined UV suppression of EAE in mice devoid of the vitamin D receptor (VDR). Our results demonstrate that UV light suppression of EAE occurs in the absence of vitamin D production and in the absence of VDR. Future investigations will focus on identifying the pathway responsible for the protective action of UV in EAE and presumably human MS.


Assuntos
Encefalomielite Autoimune Experimental/metabolismo , Encefalomielite Autoimune Experimental/terapia , Esclerose Múltipla/terapia , Fototerapia , Receptores de Calcitriol/metabolismo , Vitamina D/metabolismo , Animais , Colecalciferol/análogos & derivados , Colecalciferol/metabolismo , Modelos Animais de Doenças , Encefalomielite Autoimune Experimental/genética , Feminino , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Esclerose Múltipla/genética , Esclerose Múltipla/metabolismo , Receptores de Calcitriol/genética , Pele/metabolismo , Pele/efeitos da radiação , Raios Ultravioleta
12.
Dis Model Mech ; 11(3)2018 03 07.
Artigo em Inglês | MEDLINE | ID: mdl-29590632

RESUMO

Human studies have shown that individuals with colon cancer tend to have lower serum 25-hydroxy-vitamin D3 [25(OH)D3] levels compared with healthy controls, but whether this link is causative, a result of the disease or an indicator of another factor altogether has yet to be demonstrated. In humans, vitamin D, calcium and UV exposure are inextricably linked; therefore, understanding the individual and combined roles of each of these will require animal models specifically designed to address these questions. To begin to untangle this network, our group has employed the ApcPirc/+ rat, which contains a truncating mutation in the Apc gene, leading to the development of colonic tumors. Our group previously utilized this model to demonstrate that vitamin D supplementation above normal does not reduce colonic tumor burden and, in fact, increased tumor multiplicity in a dose-dependent manner. In the current study, we tested whether vitamin D deficiency plays a causative role in tumor development using two strains which differ in their susceptibility to intestinal tumorigenesis. In the colon, vitamin D deficiency did not increase the development of tumors in either strain, and was actually protective in one strain. Unexpectedly, low dietary calcium combined with vitamin D deficiency significantly suppressed tumor development in the small intestine and colon of both strains. The vast majority of tumors in the human intestine occur in the colon, and we find no evidence to support a direct role of vitamin D deficiency in increasing colonic tumorigenesis, and low calcium might protect against tumor development.This article has an associated First Person interview with the first author of the paper.


Assuntos
Proteína da Polipose Adenomatosa do Colo/genética , Cálcio da Dieta/uso terapêutico , Carcinogênese/patologia , Neoplasias do Colo/patologia , Neoplasias do Colo/prevenção & controle , Progressão da Doença , Substâncias Protetoras/uso terapêutico , Deficiência de Vitamina D/complicações , Proteína da Polipose Adenomatosa do Colo/metabolismo , Animais , Calcitriol/sangue , Cálcio/sangue , Cálcio da Dieta/farmacologia , Carcinogênese/efeitos dos fármacos , Carcinogênese/genética , Proliferação de Células/efeitos dos fármacos , Proliferação de Células/genética , Neoplasias do Colo/genética , Sulfato de Dextrana , Modelos Animais de Doenças , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Antígeno Ki-67/genética , Antígeno Ki-67/metabolismo , Limite de Detecção , Substâncias Protetoras/farmacologia , Ratos , Aumento de Peso/efeitos dos fármacos
13.
Drugs R D ; 17(4): 597-605, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28905271

RESUMO

BACKGROUND: 2-Methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 (DP001 or 2MD) is a novel, potent 1α-hydroxylated vitamin D analog that binds to the vitamin D receptor and suppresses parathyroid hormone synthesis and secretion with potential for an improved safety profile compared to existing active vitamin D analogs. The purpose of this study was to evaluate the pharmacokinetics of DP001 given orally after hemodialysis. METHODS: DP001 (550 ng) was given orally to 11 hemodialysis patients with secondary hyperparathyroidism after each dialysis session (3 times/week) for 4 weeks. Pharmacokinetic analyses were performed after the first and final dose. RESULTS: After the first and final dose, the half-life of DP001 was similar (55.8 ± 13.0 and 50.8 ± 8.2 h, respectively). At 4 weeks, the time to maximum plasma concentration was 4.0 ± 0.8 h, with a concentration maximum of 3.4 ± 0.3 pg/mL. The area under the curve (0 to infinity) after the final dose was 204.3 ± 23.9 pg h/mL, and apparent volume of distribution was 2.03 ± 0.22 L/kg. At week 4, mean intact parathyroid hormone was suppressed 33% from the baseline (pre-dose) value (313 ± 52 vs 462 ± 39 pg/mL, respectively). No clinically significant changes from baseline values were found for vital signs, electrocardiogram measurements, or other laboratory parameters, including serum calcium and phosphorus. CONCLUSIONS: In hemodialysis patients, DP001 has a longer half-life than existing vitamin D therapies and enables control of parathyroid hormone when administered every 2-3 days on the day of dialysis. It is effective at a lower concentration maximum and area under the curve than other clinically available vitamin D compounds. DP001 may represent a therapeutic improvement over existing compounds due to rapid and extensive distribution to its target and its long half-life enabling sustained parathyroid hormone suppression. These studies support further evaluation of DP001 in longer-term treatment of secondary hyperparathyroidism.


Assuntos
Calcitriol/análogos & derivados , Hiperparatireoidismo Secundário/tratamento farmacológico , Receptores de Calcitriol/agonistas , Diálise Renal , Insuficiência Renal Crônica/sangue , Administração Oral , Adulto , Idoso , Área Sob a Curva , Calcitriol/administração & dosagem , Calcitriol/farmacocinética , Calcitriol/uso terapêutico , Feminino , Meia-Vida , Humanos , Hiperparatireoidismo Secundário/sangue , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Insuficiência Renal Crônica/terapia
14.
Proc Natl Acad Sci U S A ; 114(32): 8528-8531, 2017 08 08.
Artigo em Inglês | MEDLINE | ID: mdl-28739922

RESUMO

UV light suppresses experimental autoimmune encephalomyelitis (EAE), a widely used animal model of MS, in mice and may be responsible for the decreased incidence of MS in equatorial regions. To test this concept further, we applied commercially available sunblock preparations to mice before exposing them to UV radiation. Surprisingly, some of the sunblock preparations blocked EAE without UV radiation. Furthermore, various sunblock preparations had variable ability to suppress EAE. By examining the components of the most effective agents, we identified homosalate and octisalate as the components responsible for suppressing EAE. Thus, salates may be useful in stopping the progression of MS, and may provide new insight into mechanisms of controlling autoimmune disease.


Assuntos
Salicilatos/farmacologia , Protetores Solares/farmacologia , Animais , Modelos Animais de Doenças , Encefalomielite Autoimune Experimental/imunologia , Encefalomielite Autoimune Experimental/terapia , Feminino , Camundongos , Camundongos Endogâmicos C57BL , Esclerose Múltipla/imunologia , Esclerose Múltipla/metabolismo , Esclerose Múltipla/terapia , Salicilatos/metabolismo , Protetores Solares/química , Protetores Solares/metabolismo , Raios Ultravioleta/efeitos adversos
15.
J Steroid Biochem Mol Biol ; 171: 144-154, 2017 07.
Artigo em Inglês | MEDLINE | ID: mdl-28285018

RESUMO

As a continuation of our efforts directed to the structure-activity relationship studies of vitamin D compounds, we present in this paper the synthesis of new analogues of 1α,25-(OH)2D3 characterized by numerous structural modifications, especially a cleaved D ring. Total synthesis of the CD fragment required for the construction of the target vitamins was based on the Stork approach. The structure of the key intermediate - bicyclic hydroxy lactone - was established by crystallographic and electronic circular dichroism (ECD) spectral analysis. Following the attachment of the hydroxyalkyl side chain, the formed D-seco Grundmann ketone was subjected to Wittig-Horner coupling with the corresponding A-ring phosphine oxides providing two desired D-seco analogues of 19-nor-1α,25-(OH)2D3, one without a substituent at C-2 and the other possessing a 2-exomethylene group. Both compounds were biologically tested and the latter was found to be more active in in vitro tests. Despite so many structural changes introduced in its structure, the biological activity of the 2-methylene analogue approached that of the natural hormone. The synthesized D-seco vitamins, however, proved to be inactive on bone and intestine in vivo.


Assuntos
Calcitriol/análogos & derivados , Desenho de Fármacos , Modelos Moleculares , Receptores de Calcitriol/agonistas , Deficiência de Vitamina D/tratamento farmacológico , Animais , Sítios de Ligação , Conservadores da Densidade Óssea/química , Conservadores da Densidade Óssea/metabolismo , Conservadores da Densidade Óssea/farmacologia , Conservadores da Densidade Óssea/uso terapêutico , Calcitriol/química , Calcitriol/metabolismo , Calcitriol/farmacologia , Calcitriol/uso terapêutico , Diferenciação Celular/efeitos dos fármacos , Fármacos Gastrointestinais/química , Fármacos Gastrointestinais/metabolismo , Fármacos Gastrointestinais/farmacologia , Fármacos Gastrointestinais/uso terapêutico , Genes Reporter/efeitos dos fármacos , Células HL-60 , Humanos , Ligantes , Masculino , Conformação Molecular , Simulação de Acoplamento Molecular , Ratos Sprague-Dawley , Receptores de Calcitriol/genética , Receptores de Calcitriol/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Estereoisomerismo , Relação Estrutura-Atividade , Vitamina D3 24-Hidroxilase/química , Vitamina D3 24-Hidroxilase/genética , Vitamina D3 24-Hidroxilase/metabolismo , Desmame
16.
BMC Neurosci ; 18(1): 8, 2017 01 05.
Artigo em Inglês | MEDLINE | ID: mdl-28056806

RESUMO

BACKGROUND: Ultraviolet B irradiation confers strong resistance against experimental autoimmune encephalomyelitis, a model of multiple sclerosis. This protection by ultraviolet B is independent of vitamin D production but causes isomerization of urocanic acid, a naturally occurring immunosuppressant. METHODS: To determine whether UCA isomerization from trans to cis is responsible for the protection against experimental autoimmune encephalomyelitis afforded by ultraviolet B, trans- or cis-urocanic acid was administered to animals and their disease progression was monitored. RESULTS: Disease incidence was reduced by 74% in animals exposed to ultraviolet B, and skin cis-urocanic acid levels increased greater than 30%. However, increasing skin cis-urocanic acid levels independent of ultraviolet B was unable to alter disease onset or progression. CONCLUSIONS: It is unlikely that urocanic acid isomerization is responsible for the ultraviolet B-mediated suppression of experimental autoimmune encephalomyelitis. Additional work is needed to investigate alternative mechanisms by which UVB suppresses disease.


Assuntos
Encefalomielite Autoimune Experimental/metabolismo , Esclerose Múltipla/metabolismo , Raios Ultravioleta , Ácido Urocânico/química , Ácido Urocânico/efeitos da radiação , Animais , Progressão da Doença , Encefalomielite Autoimune Experimental/terapia , Feminino , Isomerismo , Camundongos , Camundongos Endogâmicos C57BL , Esclerose Múltipla/terapia , Terapia Ultravioleta , Ácido Urocânico/administração & dosagem
17.
J Steroid Biochem Mol Biol ; 173: 57-63, 2017 10.
Artigo em Inglês | MEDLINE | ID: mdl-27576086

RESUMO

Prompted by results of molecular modeling performed on the seco-d-ring-vitamins D, we turned our attention to such analogs, having reversed configurations at C-13 and C-14, as the next goals of our studies on the structure-activity relationship for vitamin D compounds. First, we developed an efficient total synthesis of the "upper" C/seco-d-ring fragment with a 7-carbon side chain. Then, we coupled it with A-ring fragments using Sonogashira or Wittig-Horner protocol, providing the targeted D-seco analogs of 1α,25-dihydroxyvitamin D3 and 1α,25-dihydroxy-19-norvitamin D3 possessing a vinyl substituent at C-14 and a double bond between C-17 and C-20. The affinities of the synthesized vitamin D analogs to the full-length recombinant rat VDR were examined, as well as their differentiating and transcriptional activities. In these in vitro tests, they were significantly less active compared to 1α,25-(OH)2D3. Moreover, it was established that the analogs tested in vivo in rats showed no calcemic potency.


Assuntos
Calcitriol/análogos & derivados , Calcitriol/farmacologia , Vitaminas/química , Vitaminas/farmacologia , Animais , Calcitriol/síntese química , Calcitriol/metabolismo , Linhagem Celular , Técnicas de Química Sintética , Humanos , Simulação de Acoplamento Molecular , Ratos , Receptores de Calcitriol/metabolismo , Deficiência de Vitamina D/tratamento farmacológico , Deficiência de Vitamina D/metabolismo , Vitaminas/síntese química , Vitaminas/metabolismo
18.
Am J Nephrol ; 45(1): 40-48, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-27880946

RESUMO

BACKGROUND: Vitamin D analogs and calcimimetics are used to manage secondary hyperparathyroidism (SHPT) in dialysis patients. DP001 is an oral vitamin D analog that suppresses parathyroid hormone (PTH) in uremic rats, osteopenic women, and hemodialysis patients. The safety and effectiveness of DP001 suppressing PTH in dialysis patients previously managed with active vitamin D with or without a calcimimetic are presented. METHODS: A multicenter, randomized, double-blind study compared DP001 to placebo in hemodialysis patients with serum-intact PTH (iPTH) ≥300 pg/ml. The primary efficacy endpoint was the proportion of patients achieving 2 consecutive ≥30% decreases in iPTH levels during the 12 weeks of treatment. Calcium, phosphorus, calcium × phosphorus product and safety were also evaluated. The responses to DP001 were compared in patients previously treated with both active vitamin D and a calcimimetic to those previously on active vitamin D alone. RESULTS: Sixty-two patients were randomized (n = 34 DP001; n = 28 placebo). At week 12, 78% of all DP001-treated patients and 7% of all placebo-treated patients achieved the primary endpoint (p < 0.0001); iPTH fell 45% in the DP001 group and increased 37% in the placebo group. No patient exceeded the safety threshold of 2 consecutively corrected serum calcium levels ≥11.0 mg/dl. Patients previously on cinacalcet plus active vitamin D also responded to DP001 (n = 10) resulting in a 55% decrease in iPTH, while those on placebo (n = 9) increased by 70%. CONCLUSION: DP001 safely and effectively suppressed iPTH in hemodialysis patients with SHPT that were previously managed with active vitamin D alone or with a calcimimetic (www.clinicaltrials.gov, NCT01922843).


Assuntos
Calcitriol/análogos & derivados , Hiperparatireoidismo Secundário/tratamento farmacológico , Falência Renal Crônica/terapia , Diálise Renal , Adulto , Idoso , Calcitriol/uso terapêutico , Cálcio/metabolismo , Método Duplo-Cego , Feminino , Humanos , Hiperparatireoidismo Secundário/etiologia , Hiperparatireoidismo Secundário/metabolismo , Falência Renal Crônica/complicações , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/metabolismo , Fósforo/metabolismo , Resultado do Tratamento
19.
Am J Nephrol ; 43(3): 213-20, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27096733

RESUMO

BACKGROUND: Use of existing therapies for secondary hyperparathyroidism (SHPT), such as calcitriol or paricalcitol, is frequently limited by the development of hypercalcemia. 2-Methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 (2MD; DP001) is a novel and a more potent vitamin D receptor activator (VDRA) that more selectively localizes in the parathyroid gland, and has a wider therapeutic margin in the uremic rat model than calcitriol and paricalcitol. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: Hemodialysis patients were enrolled and dosed with 110, 220, 330, 440, or 550 ng of 2MD orally thrice weekly for 4 weeks. Responders were defined as patients having a ≥30% reduction in parathyroid hormone (PTH) from baseline, and were assessed at weeks 2 and 4. RESULTS: Of 31 patients recruited, 24 completed the 4-week treatment. There was little or no reduction in PTH in the 110 and 220 ng dose cohorts. Higher dose cohorts had greater PTH suppression with more than half the patients in the 440 and 550 ng dose cohorts considered responders (≥30% PTH reduction from baseline). None had oversuppression of PTH or hypercalcemia (corrected serum calcium >10.6 mg/dl). Plasma drug concentration increased with increasing dose, and all responders achieved a 2MD concentration of ≥1.5 pg/ml. All dose levels of 2MD were well tolerated without safety concerns. CONCLUSIONS: In hemodialysis patients with SHPT, 2MD, at thrice weekly oral doses of 440 and 550 ng, is well tolerated and effectively suppresses PTH without hypercalcemia. Future studies are needed to study the long-term implications of treating ESRD patients with this novel VDRA.


Assuntos
Calcitriol/análogos & derivados , Hiperparatireoidismo Secundário/tratamento farmacológico , Idoso , Calcitriol/uso terapêutico , Feminino , Humanos , Hiperparatireoidismo Secundário/etiologia , Falência Renal Crônica/complicações , Masculino , Pessoa de Meia-Idade
20.
Vitam Horm ; 100: 151-64, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26827952

RESUMO

Biologically active metabolites of vitamin D that have been successfully developed for the clinical market are described. Their properties that resulted in their success in the clinic are also provided. Precursors of the metabolically active 1α,25-dihydroxyvitamin D have been prepared and successfully marketed not only for renal failure patients but also for a variety of patients having metabolic bone disorders. Finally, successful analogs of 1α,25-dihydroxyvitamin D in use in the clinic worldwide are presented including properties that have contributed to their success.


Assuntos
Calcitriol/farmacologia , Cálcio/metabolismo , Vitamina D/análogos & derivados , Osso e Ossos/efeitos dos fármacos , Osso e Ossos/fisiologia , Homeostase , Humanos , Vitamina D/química , Vitamina D/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA